Please login to the form below

alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223 chloride), as well as the recently launched
FDA fast-tracks Bayer's prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin. Bayer said yesterday the US FDA had granted fast-track status to its radiotherapeutic drug for castration-resistant prostate cancer (CRPC), raising ... The FDA granted priority review
Bayer points to four blockbusters in portfolio

Alpharadin is in phase III testing for bone metastases in patients with castration-resistant prostate cancer and should be filed for approval in the US and Europe in mid-2012.
Bayer's prostate cancer drug fast-tracked

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA). ... Bayer holds the global rights to develop and commercialise Alpharadin. However, in the

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Midweight Brand Planner: Up to £50, 000

Head of Partnerships - Competitive - London: Competitive Salary Offered

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior / Principal Medical Writer / ETL - MedComms - HOME BASED ...: D.O.E

Senior Medical Writer: Salary TBC

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Playing Mind Games: To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists: P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future: As I sit here at another pharma conference, I start to reflect on how they have changed over the years....